FDA drug officials pulled few punches at a recent hearing on potential industry user fees for the OTC drug monograph program, recognizing current failings and admitting, frankly, that the agency is struggling to keep up with related science and market developments.
The monograph program was "instituted, really, many, many decades ago. We've been trying to implement it since," said Center for Drug Evaluation and Research Director Janet Woodcock in her opening...